RT @BLLPHD: #OpenAccess nice review on future prospects of #Immunotherapy as @NatureComms celebrates 10 year anniversary. From Finck, Gill,…
Cancer immunotherapy comes of age and looks for maturity. https://t.co/qEt4UyUyaK https://t.co/RfxMi5zZzu
RT @syinvesting: Here's a good recap of the last decade in #cancer #immunotherapy from @NatureComms. Article (open access): https://t.co/A…
...main challenge with ICBs is to improve efficacy, seeing that the majority of patients are resistant to therapy. Analysis of solid tumors & the tumor microenvironment have shown that responses are limited to patients with “hot” tumors, with prominent
RT @JAX_CKB: Converting "cold" tumors - nice overview of problems to be solved. #cancer #IO https://t.co/9xNMek61bV
Immunotherapy as we know now.... is it just the beginning?
RT @PTarantinoMD: Interesting comment from @NatureComms, depicting opportunities & challenges for cancer immunotherapy in the next 10 yea…
RT @PTarantinoMD: Interesting comment from @NatureComms, depicting opportunities & challenges for cancer immunotherapy in the next 10 yea…
RT @PTarantinoMD: Interesting comment from @NatureComms, depicting opportunities & challenges for cancer immunotherapy in the next 10 yea…
RT @PTarantinoMD: Interesting comment from @NatureComms, depicting opportunities & challenges for cancer immunotherapy in the next 10 yea…
Interesting comment from @NatureComms, depicting opportunities & challenges for cancer immunotherapy in the next 10 years A lot of work needed to extend responses to “cold” tumors, but rewards promise to be worth the effort @OncoAlert https://t.
In the past decade, oncology "has witnessed the transition of cancer immunotherapy from a pipe dream to an established powerful cancer treatment modality." Via @NatureComms https://t.co/5LLeKJoRVe https://t.co/0v5DcGUPFF
RT @Zihai: Nice short overview by @carlhjune and his colleagues on the future of cell/protein engineering for immunotherapy. https://t.co/s…
RT @syinvesting: Here's a good recap of the last decade in #cancer #immunotherapy from @NatureComms. Article (open access): https://t.co/A…
RT @syinvesting: Here's a good recap of the last decade in #cancer #immunotherapy from @NatureComms. Article (open access): https://t.co/A…
RT @syinvesting: Here's a good recap of the last decade in #cancer #immunotherapy from @NatureComms. Article (open access): https://t.co/A…
Here's a good recap of the last decade in #cancer #immunotherapy from @NatureComms. Article (open access): https://t.co/AaurgpBaJ8 https://t.co/TeDaoxyqET
RT @BLLPHD: #OpenAccess nice review on future prospects of #Immunotherapy as @NatureComms celebrates 10 year anniversary. From Finck, Gill,…
RT @Zihai: Nice short overview by @carlhjune and his colleagues on the future of cell/protein engineering for immunotherapy. https://t.co/s…
RT @BLLPHD: #OpenAccess nice review on future prospects of #Immunotherapy as @NatureComms celebrates 10 year anniversary. From Finck, Gill,…
RT @Zihai: Nice short overview by @carlhjune and his colleagues on the future of cell/protein engineering for immunotherapy. https://t.co/s…
What companies are on the track?
"As cancer immunotherapeutic research continues, we expect an increasing reliance on synthetic biology." https://t.co/UdmpNd3RBq
RT @BLLPHD: #OpenAccess nice review on future prospects of #Immunotherapy as @NatureComms celebrates 10 year anniversary. From Finck, Gill,…
RT @BLLPHD: #OpenAccess nice review on future prospects of #Immunotherapy as @NatureComms celebrates 10 year anniversary. From Finck, Gill,…
RT @BLLPHD: #OpenAccess nice review on future prospects of #Immunotherapy as @NatureComms celebrates 10 year anniversary. From Finck, Gill,…
#OpenAccess nice review on future prospects of #Immunotherapy as @NatureComms celebrates 10 year anniversary. From Finck, Gill, and June @PennMedicine #cancer #innovation https://t.co/TG1wHujmpT
RT @mjwsim: Cancer immunotherapy comes of age and looks for maturity | Nature Communications https://t.co/lHzYD6kbqG
RT @mjwsim: Cancer immunotherapy comes of age and looks for maturity | Nature Communications https://t.co/lHzYD6kbqG
RT @Zihai: Nice short overview by @carlhjune and his colleagues on the future of cell/protein engineering for immunotherapy. https://t.co/s…
Nice short overview by @carlhjune and his colleagues on the future of cell/protein engineering for immunotherapy. https://t.co/sDfYylaXHB https://t.co/9YxQg7Spjw
Cancer immunotherapy comes of age and looks for maturity | Nature Communications https://t.co/lHzYD6kbqG
RT @MLitbot: Cancer immunotherapy comes of age and looks for maturity. https://t.co/LG93ckLj9c https://t.co/lqlpjGSnZ6
Cancer immunotherapy comes of age and looks for maturity. https://t.co/LG93ckLj9c https://t.co/lqlpjGSnZ6
¡Publicado hoy! @NatureNews @NatureRevCancer Hemos sido testigos de la transición de la #inmunoterapia contra el #Cáncer; de ser un #SueñoImposible a una potente modalidad establecida de #TratamientovsCáncer. https://t.co/wPlf8OrunJ https://t.co/qjlbcHy